跳至主要内容
临床试验/EUCTR2007-005618-38-IT
EUCTR2007-005618-38-IT进行中(未招募)不适用

The OPG/RANKL/RANK system: implication for osteoporosis and atherosclerosis development. Potential role of the treatment with Atorvastatin - ND

.L.S.S. 9 DI TREVISO0 个研究点开始时间: 2008年2月5日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Female patients with osteoporosis (T score < -2.5) and Total plasma cholesterol >220 mg/dl;
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Patients taking hypolipidemic drugs, bisphosphonates, estrogens, raloxifene, glucorticoids; - Evidence of inflammatory or endocrine disorders, chronic renal failure, malabsorption. - Patients taking drugs that interfere with metabolism of statin by CYP3A4 (such as cyclosporin, niacin, fibrates, erythromycin and antifungal drugs)

研究者

发起方
.L.S.S. 9 DI TREVISO

相似试验